ACRV vs EXC · $65.1M cap vs P/E 17, rev $24.26B
Acrivon Therapeutics, Inc. Common Stock (ACRV) versus Exelon Corporation (EXC) — a side-by-side from cached financials, not a winner call.
Acrivon Therapeutics, Inc. Common Stock (ACRV) is a biotechnology company listed on NASDAQ.
Exelon Corporation (EXC) is a utilities - regulated electric company listed on NASDAQ.
ACRV does not have a complete income-statement cache yet.
Latest reported EXC revenue for 2025-12-31 was $24.26B. Net income was $2.77B. Revenue was up 5.3% from 2024-12-31 to 2025-12-31. EXC currently screens at market cap $47.33B and trailing P/E 16.8.
ACRV currently screens at market cap $65.1M. EXC currently screens at market cap $47.33B and trailing P/E 16.8.
Not investment advice. Open the ACRV and EXC stock pages for the full models.
Not investment advice.